Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
11.07
-0.16 (-1.42%)
Nov 21, 2024, 1:46 PM EST - Market open
Replimune Group Employees
Replimune Group had 331 employees as of March 31, 2024. The number of employees increased by 47 or 16.55% compared to the previous year.
Employees
331
Change (1Y)
47
Growth (1Y)
16.55%
Revenue / Employee
n/a
Profits / Employee
-$643,571
Market Cap
757.38M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Bioventus | 970 |
Pacira BioSciences | 712 |
Adaptive Biotechnologies | 709 |
Evolus | 273 |
Prothena Corporation | 173 |
Pliant Therapeutics | 158 |
CARGO Therapeutics | 116 |
Dianthus Therapeutics | 53 |
REPL News
- 12 days ago - Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) - GlobeNewsWire
- 12 days ago - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewsWire
- 6 weeks ago - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire
- 2 months ago - Replimune: Strong Data In A Highly Differentiated Space - Seeking Alpha
- 3 months ago - Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma - GlobeNewsWire
- 4 months ago - Replimune to Present at Two Upcoming Investor Conferences - GlobeNewsWire